FY2025 · ended Dec 31, 2025 · Revenue $0, -100.0% YoY · Filed Feb 24, 2026
Fulcrum Therapeutics, Inc. (FULC) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $74.9 million. Free cash flow was -$60.4 million. As of Jun 30, 2026 it held $318.8 million in cash and investments and $5.3 million in total debt.
Revenue
$0
-100.0% vs prior year
Net income
$-74.88M
-670.0% vs prior year
Operating cash flow (TTM)
$-65.78M
-1.3% vs year-ago TTM
Free cash flow (TTM)
$-66.14M
-1.4% vs year-ago TTM
EPS
$-1.18
-637.5% vs prior year
Dividend per share
None
Shares outstanding
66.60M
+23.4% vs prior year
Net cash
$313.56M
as of Jun 30, 2026
Operating margin
-27.4%
FY 2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- FULC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1680581
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $80.0M | $2.8M | $6.3M | $19.2M |
| Operating income | -$84.8M | -$21.9M | -$110.7M | -$112.6M | -$81.1M |
| Net income | -$74.9M | -$9.7M | -$97.3M | -$109.9M | -$80.8M |
| Diluted EPS | -$1.18 | -$0.16 | -$1.59 | -$2.44 | -$2.29 |
| Operating cash flow | -$60.1M | -$2.2M | -$91.0M | -$97.0M | -$78.5M |
| Free cash flow | -$60.4M | -$2.5M | -$91.5M | -$99.0M | -$80.2M |
| Total assets | $366.3M | $260.7M | $257.7M | $226.7M | $235.0M |
| Total liabilities | $17.3M | $17.7M | $22.5M | $27.7M | $23.5M |
| Stockholders' equity | $349.0M | $243.0M | $235.2M | $198.9M | $211.5M |
| Cash and investments | $352.3M | $241.0M | $236.2M | $202.9M | $218.2M |
| Total debt | $6.4M | $8.6M | $10.8M | $13.4M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale, Change in control, Officer or director change, Regulation FD disclosure
|
Aug 17, 2026 | Aug 16, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 10, 2026 | Aug 7, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 25, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 11, 2026 | Jun 5, 2026 |
| 8-K |
Current report
Exit or restructuring costs, Other events
|
Jun 4, 2026 | May 31, 2026 |
All 520 Fulcrum Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.